Reactome | IFNGR1:JAK1:INFGR2:JAK2 binds JAK1,2 inhibitors

IFNGR1:JAK1:INFGR2:JAK2 binds JAK1,2 inhibitors

Stable Identifier

R-HSA-9678561

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

IFNGR1:JAK1:INFGR2:JAK2 binds JAK1,2 inhibitors

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Janus Kinase 2 (JAK2) binds and is inhibited by several small molecule drugs (Clark et al. 2014, Fridman et al. 2010, Hanan et al. 2012). The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases such as baricitinib, tofacitinib and ruxolitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Literature References

PubMed ID	Title	Journal	Year
24417533	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases Clark, JD, Telliez, JB, Flanagan, ME	J. Med. Chem.	2014
20130243	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Li, J, Quintás-Cardama, A, Rupar, M, Manshouri, T, Kantarjian, H, Burn, T, Wen, X, Lo, Y, Liu, P, Verstovsek, S, Covington, M, Scherle, PA, Kelley, J, Waeltz, P, Caulder, E, Shepard, S, Vaddi, K, Fridman, JS, Haley, P, Li, Y, Rodgers, JD	Blood	2010
23061660	Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors Chang, C, Siu, M, Murray, J, Sampath, D, Rawson, T, Ultsch, M, Hurley, CA, Gibbons, P, Pastor, RM, Eigenbrot, C, Zhou, A, Morris, C, Barrett, K, Kenny, JR, Hanan, EJ, Flynn, S, Kulagowski, J, van Abbema, A, Blair, WS, Blaney, J, Lee, L, Magnuson, SR, Lyssikatos, JP	J. Med. Chem.	2012
20363976	Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 Favata, MF, Shi, J, Yeleswaram, S, Li, J, Metcalf, B, Wen, X, Scherle, PA, Thomas, B, McGee, R, Collins, R, Newton, RC, Burn, TC, Covington, MB, Friedman, SM, Shepard, S, Haley, PJ, Vaddi, K, Hollis, G, Fridman, JS, Li, Y, Rodgers, JD, Collier, P	J. Immunol.	2010